Salute e Benessere

Zymeworks Presents New Data from Multiple Preclinical Development Programs at…

“Our team is looking forward to share new data from our strong portfolio of multispecific antibody therapeutics and antibody-drug conjugates including ZW191, an anticipated 2024 IND candidate,” said Paul Moore, Ph.D., Chief Scientific Officer at Zymeworks. “These data provide important new insights highlighting the potential of our candidates to represent major advances in the treatment of cancer while also demonstrating the potential to develop a new generation of novel antibody-drug...
Nasdaq GlobeNewswire
08/04/2024

Share-based legacy RSU program granted

Share-based legacy RSU program grantedNovonesis' Board of Directors has following the merger with Chr. Hansen Holding A/S (“Chr. Hansen”) today approved the continuation in 2024 of a legacy Chr. Hansen annual short-term incentive program comprising of up to 125,000 restricted share units (RSUs) for around 130 legacy Chr. Hansen key employees below the Executive Management level. Receipt of the RSUs is subject to specified KPIs and criteria supporting performance and retention...
Nasdaq GlobeNewswire
08/04/2024

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; April 8, 2024 – Genmab A/S (Nasdaq: GMAB).On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares.The share buy-back program is expected to be completed no later than December 16, 2024.The following transactions were executed under the program from April 1, 2024 to April 5, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)...
Nasdaq GlobeNewswire
08/04/2024

Notice to extraordinary general meeting in Scibase Holding AB (publ)

Right to participate and notice of participation Right to participate and notice of participation A shareholder who wishes to participate at the extraordinary general meeting must: (i) be recorded in the share register maintained by Euroclear Sweden AB on2 May 2024, and (ii) notify the Company of its intention to participate by post to Advokatfirman Schjødt, Box 715, 101 33 Stockholm, or by e-mail towilliam.hellsten@schjodt.com, no later than6 May 2024...
PR Newswire
08/04/2024

Vivet Therapeutics Doses First Patient in Cohort 2 in Phase 1/2 GATEWAY Clinical…

PARIS, April 8, 2024 /PRNewswire/ -- Vivet Therapeutics ('Vivet'), a clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited liver metabolic disorders, today announces that it has dosed its first patient with its lead program VTX-801 in Cohort 2 of its ongoing GATEWAY Clinical Trial for the treatment of Wilson Disease (WD). Initiation of Cohort 2 followed the successful completion of Cohort 1 and approval from an independent Data Monitoring Committee…
PR Newswire
08/04/2024

Curium Plans to Significantly Expand Lutetium-177 Capacity and Pet Footprint…

The proposed acquisition of Eczacıbaşı-Monrol will:Build on existing partnership in Lu-177 creating a leading manufacturer of the isotopeAdd 12 PET sites to Curium's existing network in geographies where Curium is not present todayAdd SPECT manufacturing capabilities and extensive logistics infrastructure to CuriumBenefit patients with strengthened reliability for diagnostic and therapeutic solutions PARIS, April08, 2024(GLOBE NEWSWIRE) -- Curium, a world leader in nuclear...
Nasdaq GlobeNewswire
08/04/2024

Calliditas receives notice of allowance for United States patent application…

"This is a significant value enhancing event for the global setanaxib franchise and we are delighted that we are able to expand product protection for setanaxib in the important area of oncology," said CEO Renée Aguiar-Lucander. "This is a significant value enhancing event for the global setanaxib franchise and we are delighted that we are able to expand product protection for setanaxib in the important area of oncology," said CEO Renée Aguiar-Lucander. Calliditas has…
PR Newswire
08/04/2024

Medicxi Announces $40m investment in D3 Bio

D3S-001 is a new generation small molecule KRAS G12C inhibitor with differentiated properties and could potentially address the still large unmet need of patients with cancers harboring KRAS G12C mutations. D3S-001 is currently in phase II development in non-small cell lung cancer, colorectal cancer and pancreatic cancer. D3S-001 is a new generation small molecule KRAS G12C inhibitor with differentiated properties and could potentially address the still large unmet need of patients with...
PR Newswire
08/04/2024

Deepening the Partnership: Dawn Health Introduces Ekiva for Enhanced Disease…

Last year saw the launch of the first Ekiva solution from Dawn Health and Novartis, providing people with Multiple Sclerosis a solution to support them in the everyday management of their MS. Ekiva MS was in the hands of its first users in only six months, and with +25.000 downloads in its first 6 months, it's clearly showing the market's need for these innovative solutions. Last year saw the launch of the first Ekiva solution from Dawn Health and Novartis, providing people with Multiple...
PR Newswire
08/04/2024

Glycotope to present platform approach for development of anti-GlycoTarget…

Glycotope to present platform approach for development of anti-GlycoTarget antibodies at 2024 AACR Meeting Berlin, Germany, 08 April, 2024 – Glycotope GmbH, a biotechnology company utilizing a proprietary platform technology to developing antibodies against proteins carrying tumor-specific carbohydrate structures, today announces that it will present its platform approach and GlycoTarget database in a poster presentation at the 2024 American Association for Cancer Research (AACR)...
Nasdaq GlobeNewswire
08/04/2024

Pharming announces completion of enrollment in pediatric clinical trial of…

This multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency Leiden, the Netherlands, April 8, 2024:Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces the completion of patient enrollment in its Phase III clinical trial (NCT05438407) evaluating the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in...
Nasdaq GlobeNewswire
08/04/2024

iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell…

Based on the Company's discovery and characterization of ENT1 in adenosine-mediated immunosuppression, this novel mechanism allows for the intracellular accumulation of adenosine, which then suppresses proliferation and effector function of T cells in the high adenosine tumor microenvironment. In mouse models, deletion of ENT1 led to potent control of tumor proliferation and increased CD8+ T cell frequency, proliferation, and cytokine production within tumors,further supporting ENT1's...
Nasdaq GlobeNewswire
07/04/2024

Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy…

Three-year follow-up data of an investigator-initiated Phase 1 trial of the individualized mRNA cancer vaccine candidate autogene cevumeran (BNT122, RO7198457) continue to show polyspecific T cell responses up to three years and delayed tumor recurrence in patients with resected pancreatic ductal adenocarcinoma (“PDAC”)A randomized Phase 2 clinical trial with autogene cevumeran in patients with resected PDAC is currently enrolling patients at clinical trial sites in the United...
Nasdaq GlobeNewswire
07/04/2024

Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the…

Renal carcinoma is the third most common malignancy of the urinary system globally, and RCC accounts for 80%~90% of all cases of renal carcinoma. There were approximately 77,000 new cases of and 46,000 deaths due to renal carcinoma in China in 2022. Distant metastasis occurred in about one-third of renal carcinoma patients at initial diagnosis, and in 20%-50% of localized patients after nephrectomy. According to the risk classification of the International Metastatic Renal Cell Carcinoma...
Nasdaq GlobeNewswire
07/04/2024

New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran)…

V-INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal on statin therapy alone led to significant LDL-C reduction vs. clinician-determined usual care (60% vs. 7% respectively) 1 A significantly greater proportion of the ASCVD patients receiving Leqvio achieved guideline-recommended LDL-C goal vs. the usual care arm while maintaining adherence to statin treatment 1 Results from...
Nasdaq GlobeNewswire
06/04/2024

Avacta Group - AVA6000 Abstract Release by AACR and Full Presentation Update

5 April 2024 Avacta Group plc(“Avacta” or “the Group” or “the Company”) AVA6000 Abstract Release by AACR and Full Presentation Update Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces that the abstract of the poster to be presented at the American Association of Cancer Research (“AACR”) Annual Meeting in San Diego, California on Tuesday 9 April has now been released by AACR.The poster...
Nasdaq GlobeNewswire
05/04/2024

CDR-Life Unveils Results on T-Cell Engagers Targeting Hard-to-Treat Solid Tumors…

Preclinical data shows promising anti-tumor activity and specificity for KK-LC-1/HLA-A*01 positive tumors CDR-Life Inc.today announced the presentation of preclinical data demonstrating the promising anti-tumor properties of its peptide major histocompatibility complex (pMHC) T-cell engager (TCE) antibodies at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place this week in San Diego, California. The Kita-Kyushu lung cancer antigen-1 (KK-LC-1/CT83) is a...
Nasdaq GlobeNewswire
05/04/2024

GENFIT Announces Publication of the 2023 Universal Registration Document and the…

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 5, 2024-GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the filing of its 2023 Universal Registration Document with theAutorité des marchés financiers(AMF ; filing n° D.24-0246) and its Annual Report on Form 20-F for the year ended December 31, 2023 with the U.S...
Nasdaq GlobeNewswire
05/04/2024

NeuroVigil, World's Most Valuable Neurotech, Launches iBrain™ in US

CLOSED 6 BILLION DOLLAR SERIES B DEAL In the first phase of the launch, iBrain, positioned as an investigational device, will hunt for biomarkers of apnea, aneurysms and drug side effects in asymptomatic individuals, as it has in partnership with Roche and Novartis, NeuroVigil's first paying clients since well over a decade. The investigators will initially not be allowed to modify anyone's therapy based on iBrain data. That can only happen following FDA-approved tests. In the second...
Nasdaq GlobeNewswire
05/04/2024

Availability of the 2023 Universal Registration Document, including the Annual…

Press Release Paris – April 5, 2024– EUROAPI announces the publication of its 2023 Universal Registration Document, filed with the FrenchAutorité des marchés financiers(AMF) on April 5, 2024.The 2023 Universal Registration Document includes in particular: The annual financial report;The Board of Directors' corporate governance report;The information about social, environmental, and societal responsibility (including the extra-financial performance declaration);...
Nasdaq GlobeNewswire
05/04/2024

PHAXIAM Therapeutics announces filing of its 2023 Universal Registration…

Lyon (France) and Cambridge (MA, US), 5 April 2024 – 6:00pm CEST - PHAXIAM Therapeutics (Euronext: PHXM; FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections,today announced that it has filed its Universal Registration Document with theAutorité des Marchés Financiers(AMF) in France for the financial year ending 31 December 2023. This document, including the annual financial report and the Board of Directors' report...
Nasdaq GlobeNewswire
05/04/2024

Antacids Market Projected to Reach $10.18 billion by 2030 - Exclusive Report by…

A significant rise in the demand for antacid medications is observed in response to the increasing global incidence of gastric conditions such as gastroesophageal reflux disease (GERD), heartburn, and peptic ulcers. These over-the-counter remedies work by neutralizing stomach acid and are available in a variety of forms, including chewable tablets, liquids, and powders, to cater to diverse consumer preferences. Lifestyle factors, including modern dietary habits, have significantly contributed to…
PR Newswire
05/04/2024

Companion Diagnostics Market Worth $13.6 billion | MarketsandMarkets™

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=155571681 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=155571681 Browse in-depth TOC on "Companion Diagnostics Market" 320 - Tables 52 - Figures 300 - Pages Companion Diagnostics Market Scope: The assays, reagents & kits segment accounted for the largest share of the companion diagnostics market, by product & service...
PR Newswire
05/04/2024

SciBase resolves on a directed issue of approximately SEK 33 million and a…

In addition, the Board of Directors of SciBase has, due to the contemplated Capital Raising, resolved to postpone the Annual General Meeting, from 17 May 2024 to 13 June 2024, and change the date for publication of the interim report for the first quarter of 2024, from 9 May 2024 to 31 May 2024. In addition, the Board of Directors of SciBase has, due to the contemplated Capital Raising, resolved to postpone the Annual General Meeting, from17 May 2024to13 June 2024, and change the date...
PR Newswire
05/04/2024
Altri  Comunicati